Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fourth leading cause of cancer-related mortality worldwide, with China accounting for over half of the global annual cases and deaths.
Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III